We developed fundamental expertise in four groups of technologies to identify the best investment targets
CAR T-cells, RNAi and CRISPR technologies that modify the expression of an individual’s genes or may potentially repair abnormal genes
Restoring certain cell populations or using cells as carriers of therapeutic cargo
Aimed to prevent or mitigate infections, as well as treatment of viral, fungal and bacterial infections
Stimulate the patient's innate immune system to attack pathogen cells
Reverse the damage that accumulates with age and leads to tissue dysfunction: accumulated genetic damage; Epigenetic alterations; Aging-associated changes in cell signaling; Loss of telomere-protective sequences
Focus on novel therapeutic approaches aimed at meeting unmet needs in either blockbuster (cancer, cardiovascular diseases) or orphan disease indications
Replacement of dysfunctional cells, tissues and organs (appearing as a result of stroke, hepatitis, chronic renal insufficiency, etc.) with healthy ones
If you are an investor interested in learning more about our fund, please send us a message
651 N. Broad St. Middletown, DE, 19709, USA